Suppr超能文献

T细胞参与大疱性类天疱疮中对NC16a表位的自身反应性。

T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

作者信息

Pickford W J, Gudi V, Haggart A M, Lewis B J, Herriot R, Barker R N, Ormerod A D

机构信息

The Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

出版信息

Clin Exp Immunol. 2015 May;180(2):189-200. doi: 10.1111/cei.12566.

Abstract

Bullous pemphigoid is a blistering skin disease characterized by autoantibodies against the NC16a domain of bullous pemphigoid 180. This study was performed to characterize and map the fine specificity of T cell responses to NC16a. Peripheral blood mononuclear cells (PBMC) from a total of 28 bullous pemphigoid patients and 14 matched controls were tested for proliferative and cytokine responses to recombinant NC16a and a complete panel of 21 overlapping peptides spanning this region of BP180. Proliferative responses to NC16A and the peptide panel in the patients with active disease were similar in frequency and magnitude to those in healthy donors, and included late responses typical of naive cells in approximately 60% of each group. Interleukin (IL)-4 responses were slightly stronger for six peptides, and significantly stronger for Nc16a, in patients than in controls. Factor analysis identified factors that separate responses to the peptide panel discretely into IL-4, T helper type 2 (Th2) pattern, interferon (IFN)-γ, Th1 pattern and IL-10 or transforming growth factor [TGF-β, regulatory T cell (Treg )] pattern. Factors segregating IL-10 versus IFN-γ were predicted by active blistering or remission, and TGF-β or IL-10 versus IFN-γ by age. Finally, we confirmed a significant up-regulation of IgE responses to BP180 in the patients with pemphigoid. This shows the complexity of T cell phenotype and fine autoreactive specificity in responses to NC16A, in patients and in normal controls. Important disease-associated factors determine the balance of cytokine responses. Of these, specific IL-4 and IgE responses show the strongest associations with pemphigoid, pointing to an important contribution by Th2 cytokines to pathogenesis.

摘要

大疱性类天疱疮是一种以针对大疱性类天疱疮180的NC16a结构域的自身抗体为特征的水疱性皮肤病。本研究旨在表征和定位T细胞对NC16a反应的精细特异性。对总共28例大疱性类天疱疮患者和14例匹配对照的外周血单个核细胞(PBMC)进行检测,以观察其对重组NC16a以及覆盖BP180该区域的一组完整的21个重叠肽段的增殖和细胞因子反应。活动性疾病患者对NC16A和肽段组的增殖反应在频率和强度上与健康供者相似,并且每组中约60%的反应包括幼稚细胞典型的晚期反应。与对照相比,患者中六种肽段的白细胞介素(IL)-4反应略强,而对Nc16a的反应则显著更强。因子分析确定了将对肽段组的反应离散地分为IL-4、2型辅助性T细胞(Th2)模式、干扰素(IFN)-γ、Th1模式以及IL-10或转化生长因子[ TGF-β,调节性T细胞(Treg)]模式的因子。通过活动性水疱或缓解情况可预测区分IL-10与IFN-γ的因子,而通过年龄可预测区分TGF-β或IL-10与IFN-γ的因子。最后,我们证实类天疱疮患者中对BP180的IgE反应显著上调。这表明在患者和正常对照中,T细胞表型以及对NC16A反应中的精细自身反应特异性具有复杂性。重要的疾病相关因素决定了细胞因子反应的平衡。其中,特定的IL-4和IgE反应与类天疱疮的关联最为密切,表明Th2细胞因子对发病机制具有重要作用。

相似文献

1
T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.
Clin Exp Immunol. 2015 May;180(2):189-200. doi: 10.1111/cei.12566.
2
Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
J Invest Dermatol. 2005 Sep;125(3):467-72. doi: 10.1111/j.0022-202X.2005.23853.x.
3
Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Arch Dermatol Res. 2015 Nov;307(9):849-54. doi: 10.1007/s00403-015-1598-3. Epub 2015 Sep 24.
5
Rapid effector function of circulating NC16A-specific T cells in individuals with mucous membrane pemphigoid.
Br J Dermatol. 2004 Dec;151(6):1160-4. doi: 10.1111/j.1365-2133.2004.06219.x.
8
Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Front Immunol. 2021 Mar 25;12:569287. doi: 10.3389/fimmu.2021.569287. eCollection 2021.
10
IgE autoantibodies against the intracellular domain of BP180.
Br J Dermatol. 2009 Feb;160(2):429-32. doi: 10.1111/j.1365-2133.2008.08858.x. Epub 2008 Sep 19.

引用本文的文献

2
Autoimmune bullous diseases: pathogenesis and clinical management.
Mol Biomed. 2025 May 15;6(1):30. doi: 10.1186/s43556-025-00272-9.
4
Bullous pemphigoid.
Nat Rev Dis Primers. 2025 Feb 20;11(1):12. doi: 10.1038/s41572-025-00595-5.
5
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Am J Clin Dermatol. 2024 Mar;25(2):195-212. doi: 10.1007/s40257-023-00832-1. Epub 2023 Dec 29.
6
Study of cytokine-induced immunity in bullous pemphigoid: recent developments.
Ann Med. 2023;55(2):2280991. doi: 10.1080/07853890.2023.2280991. Epub 2023 Dec 18.
7
Understanding CD4 T cells in autoimmune bullous diseases.
Front Immunol. 2023 Apr 17;14:1161927. doi: 10.3389/fimmu.2023.1161927. eCollection 2023.
8
Adaptive and innate immune pathogenesis of bullous pemphigoid: A review.
Front Immunol. 2023 Mar 10;14:1144429. doi: 10.3389/fimmu.2023.1144429. eCollection 2023.
9
Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy.
Front Immunol. 2023 Feb 16;14:1115083. doi: 10.3389/fimmu.2023.1115083. eCollection 2023.
10
The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.
Front Med (Lausanne). 2023 Feb 6;10:1128154. doi: 10.3389/fmed.2023.1128154. eCollection 2023.

本文引用的文献

1
Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid.
PLoS One. 2013 Jul 5;8(7):e68145. doi: 10.1371/journal.pone.0068145. Print 2013.
2
Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid.
J Eur Acad Dermatol Venereol. 2014 Feb;28(2):222-30. doi: 10.1111/jdv.12091. Epub 2013 Jan 18.
3
Detection of IgG and IgE reactivity to BP180 using the ISAC® microarray system.
Br J Dermatol. 2013 Jun;168(6):1205-14. doi: 10.1111/bjd.12161.
4
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Clin Immunol. 2012 Jun;143(3):236-45. doi: 10.1016/j.clim.2012.02.003. Epub 2012 Mar 13.
5
Incidence and mortality of bullous pemphigoid in France.
J Invest Dermatol. 2012 Aug;132(8):1998-2004. doi: 10.1038/jid.2012.35. Epub 2012 Mar 15.
6
Transcutaneous gene gun delivery of hNC16A Induces BPAG2-specific tolerance.
J Invest Dermatol. 2012 Jun;132(6):1665-71. doi: 10.1038/jid.2012.19. Epub 2012 Mar 1.
7
Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients.
Arch Dermatol Res. 2012 Oct;304(8):639-45. doi: 10.1007/s00403-012-1213-9. Epub 2012 Feb 5.
8
Successful management of severe infant bullous pemphigoid with omalizumab.
Br J Dermatol. 2012 May;166(5):1140-2. doi: 10.1111/j.1365-2133.2011.10748.x. Epub 2012 Mar 2.
9
Lesional Th17 cells and regulatory T cells in bullous pemphigoid.
Exp Dermatol. 2011 Dec;20(12):1022-4. doi: 10.1111/j.1600-0625.2011.01378.x. Epub 2011 Oct 20.
10
Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.
J Invest Dermatol. 2011 Nov;131(11):2271-80. doi: 10.1038/jid.2011.180. Epub 2011 Jun 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验